NCT02932345终止不适用
A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- Proportion of patients with specific genomic alterations(mutation, copy number change and fusion) of short or long-term survivors
研究概览
简要总结
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For inclusion in the long-term survivors group, the study subjects must fulfil the following criteria at the time of screening:
- •Provision of informed consent or EC approve informed consent waiver prior to any study specific procedures
- •Histological or cytological confirmed locally advanced NSCLC (stage III B) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
- •EGFR mutation positive
- •Patients who continuously received gefitinib for at least 3 years without evidence of PD
- •Patients with OS ≥ 5 years from NSCLC diagnosis will be preferred
- •Collect archival tumour tissue before gefitinib treatment (blood and re-biopsy tumour tissue are optional); tumor tissue samples requirements: 1) slices requirements: >1 cm2, thickness 4-5 μm, ≥ 15 slices. or, whole FFPE block; 2) tumor percentage > 20% and necrosis < 30% by pathology QC.
- •For inclusion in the rapid PD group, the study subjects must fulfil the following criteria:
- •Provision of informed consent or EC approve informed consent waiver prior to any study specific procedures
- •Histological or cytological confirmed locally advanced NSCLC (stage III B) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
- •EGFR mutation positive
- •Patients who had undergone PD after gefitinib treatment≤3 months (Rapid PD)
- •Collect archival tumour tissue before gefitinib treatment (blood and re-biopsy tumour tissue samples are optional) ; tumor tissue samples requirements: 1) slices requirements: >1 cm2, thickness 4-5 μm, ≥ 15 slices. or, whole FFPE block; 2) tumor percentage > 20% and necrosis < 30% by pathology QC.
排除标准
- •For the active patients, who must not enter the study if any of the following exclusion criteria are fulfilled
- •Patients who disagree to participate this study.
- •For the terminated patients, who must not enter the study if any of the following exclusion criteria are fulfilled
- •Patients in whose medical objection was recorded to use the existing data from medical practice for scientific research.
结局指标
主要结局
Proportion of patients with specific genomic alterations(mutation, copy number change and fusion) of short or long-term survivors
时间窗: at time of sample collection before Gefitinib treatment initiation, up to 10 years before study start
次要结局
- EGFR mutation status(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Sex(at time of Gefitinib treatment initiation,up to 10 years before study start)
- Age(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Pre-existing comorbidities at initiation of gefitinib therapy(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Histological subtype(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Smoking status(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Gefitinib treatment patterns- Dose reductions, treatment interruptions, discontinuation including reasons(from Gefitinib treatment initiation to Gefitinib treatment discontinuation or study completion, whichever occurred first, up to 12 years)
- Progression Free Survival (PFS)(from Gefitinib treatment initiation to disease progression or study completion, whichever occurred first, up to 12 years)
- Cancer type and date of first ever cancer diagnosis(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Location(s) of metastatic disease at initiation of gefitinib therapy for subjects with TNM stage IV disease(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Gefitinib treatment patterns- Types of other systemic therapies given in combination with gefitinib(from Gefitinib treatment initiation to Gefitinib treatment discontinuation or study completion, whichever occurred first, up to 12 years)
- Gefitinib treatment patterns- Starting dose(at time of Gefitinib treatment initiation, up to 10 years before study start)
- ECOG performance status at time of Gefitinib treatment initiation(at time of Gefitinib treatment initiation, up to 10 years before study start)
- Therapeutic agent name post-gefitinib discontinuation(from gefitinib discontinuation to one year post- gefitinib discontinuation, around one year)
- Documented tumour response (complete or partial response or stable disease, according to RECIST) as determined by the treating physician by clinical judgment and/or imaging after first ever initiation of gefitinib(from Gefitinib treatment initiation to study completion, up to 12 years)
- Overval survival (OS)(from Gefitinib treatment initiation to death or study completion, whichever occurred first, up to 12 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Long Term Follow-up on Menkes Disease PatientsMenkes DiseaseNCT04337684Sentynl Therapeutics, Inc.50
已完成
不适用
Long-term Data Collection for Subjects in MDX-010 StudiesMetastatic MelanomaNCT00928031Bristol-Myers Squibb160
招募中
不适用
Survival Significance of Molecular Pathology and Genetic Variation in Brain GliomasMolecular Sequence VariationGenetic ChangeGliomaNCT04216537The First Affiliated Hospital of Zhengzhou University3,000
Unknown
不适用
Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer CareMetastatic CancerAdvanced CancerCancers That Cannot be Treated With Curative IntentNCT04141397British Columbia Cancer Agency1,200
已完成
不适用
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileMultiple MyelomaNCT01454297Multiple Myeloma Research Foundation1,154